61413-44-3

Basic information

• Product Name: N-(3,4-diMethoxyphenethyl)-4-(4-Methoxyphenyl)butan-2-aMine
• Synonyms: N-(3,4-diMethoxyphenethyl)-4-(4-Methoxyphenyl)butan-2-aMine
• CAS NO: 61413-44-3
• Molecular Formula: C₂₁H₂₉NO₃
• Molecular Weight: 343.45986
• Mol File: 61413-44-3.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(3,4-diMethoxyphenethyl)-4-(4-Methoxyphenyl)butan-2-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3,4-diMethoxyphenethyl)-4-(4-Methoxyphenyl)butan-2-aMine(61413-44-3)
• EPA Substance Registry System: N-(3,4-diMethoxyphenethyl)-4-(4-Methoxyphenyl)butan-2-aMine(61413-44-3)

Safety Data

• Hazardous Substances Data: 61413-44-3(Hazardous Substances Data)

Usage

General Description

N-(3,4-dimethoxyphenethyl)-4-(4-methoxyphenyl)butan-2-amine, also known as 25B-NBOMe, is a potent psychedelic drug and a derivative of the phenethylamine hallucinogen 2C-B. It acts as a powerful agonist for the 5-HT2A receptor, a subtype of serotonin receptor, resulting in hallucinogenic effects such as visual and auditory distortions, altered perceptions of time and space, and feelings of euphoria and empathy. The compound has been associated with a number of serious adverse effects, including seizures, cardiovascular complications, and even fatalities. Its recreational use is illegal in many countries due to its potential for harm.

Upstream product

• 104-20-1 4-(4-methoxyphenyl)-2-butanone 
• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 
• 702-23-8 2-(4-Methoxyphenyl)ethanol 
• 3815-30-3 4-(4-methoxyphenyl)-3-buten-2-one 

Downstream Products

• 51062-14-7 N-[1-methyl-3-(4-methoxyphenyl)propyl]-2-(3,4-dimethoxyphenyl)ethylamine hydrochloride 
• 34368-04-2 dobutamine 

Relevant articles and documents

Preparation method of dobutamine hydrochloride intermediate compound

The invention discloses a preparation method of a dobutamine hydrochloride intermediate compound. According to the method, 3, 4-dimethoxyphenylethylamine and 4-(4-methoxyphenyl)-2-butanone are adoptedas the starting materials, acetic acid is adopted as a catalyst, cyclohexane is adopted as a reflux water diversion agent, reflux water diversion is performed to obtain a condensation product, potassium borohydride is adopted for further hydrogenation reduction, and hydrochloric acid salification is performed to obtain a crude product of a dobutamine hydrochloride intermediate. Isopropanol is adopted for refluxing and dissolving, an inorganic salt generated in the preparation process of the intermediate is removed through filtering while the solution is hot, and refining is conducted to obtain the dopamine hydrochloride intermediate. According to the method, high-pressure catalytic hydrogenation operation in the prior art is avoided, potential safety hazards are greatly reduced, meanwhile, an expensive metal catalyst is prevented from being used, and the production cost is reduced; and the use of some high-toxicity reagents and genotoxic reagents is avoided.

Method for increasing cardiac contractility

N-Mono or dihydroxyphenylalkyl dopamine derivatives and salts thereof are inotropic agents useful in a method for treatment of acutely depressed cardiac insufficiency.